Loxo Oncology, in collaboration with Lilly, is focused on developing a diverse pipeline of innovative cancer treatments. Their approach emphasizes a patient-centric philosophy, ensuring that the drugs they pursue not only demonstrate efficacy but also address significant unmet medical needs. The company employs a rigorous selection process for its research programs, concentrating on high-confidence targets that have the potential for substantial clinical impact. This commitment to scientific integrity is reflected in their collaborative culture, where interdisciplinary teams work together to accelerate drug discovery and development.

The organization fosters an environment that encourages open communication and collaboration among scientists, allowing for rapid progress in research initiatives. Loxo Oncology's structure resembles that of a dynamic biotech firm, enabling quick decision-making based on scientific data rather than bureaucratic constraints. This agility is complemented by access to cutting-edge technologies and resources, which empower their teams to explore innovative solutions in oncology. Overall, Loxo Oncology's commitment to a science-driven, patient-focused approach positions them as a leader in the field of cancer therapeutics.

United States

Loxo@Lilly aims to create medicines that make life better for all those affected
by cancer around the world. Bringing together the focus and spirit of a biotech
with the scale, resources, and heritage of Lilly, our team is focused on rapidly
delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients.

Loxo@Lilly is a global organization with team members in Boulder, Colorado; Indianapolis, Indiana; New York City, New York; San Diego, California; South San Francisco, California; Stamford, Connecticut; and Madrid, Spain.

Cancer

Immune System Diseases

Lymphatic Diseases

Skin Diseases

Urogenital Diseases

Loxo Oncology 

Chronic lymphocytic leukemia

Pirtobrutinib

Small Molecule Pharmaceuticals

Castration-resistant prostate cancer

Metastatic breast cancer

Prostate cancer

Abemaciclib

Non-small cell lung carcinoma

Selpercatinib

Imlunestrant

Biologics

Mantle cell lymphoma

B-cell malignancies

FGFR3 selective drug

KRAS G12C inhibitor drug

Next-Gen RET inhibitor drug

PI3Kα inhibitor drug

Connecticut

Therapeutic

Loxo Oncology

Company Details